Opinion|Videos|September 11, 2024
Central Precocious Puberty Treatment Starts, Discontinuations and Misconceptions
Experts address common misconceptions about the timing of central precocious puberty treatment initiation and discontinuation, highlighting research on outcomes for therapy started before age 7 and continued beyond age 12.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are common misconceptions regarding the timing of therapy initiation and discontinuation?
- What has research shown regarding outcomes for initiating therapy before age 7 years or discontinuing therapy after age 12 years?
- What consideration should clinicians give about the time to first menses after treatment cessation?
Advertisement
Related to this article
Glucommander Pediatrics received FDA Breakthrough Device Designation for IV insulin dosing in hospitalized children younger than 2 years, but remains uncleared.
ISPAD, EASD, and ADA urge pediatric diabetes teams to build center-specific transition policies, use readiness checklists, and ensure timely handoffs to adult clinicians.
Semaglutide cut testosterone by half in early trial data — but one patient's rapid weight loss revealed a real risk. Our experts weigh the promise of GLP-1 therapy against how fast is too fast for teens.
Which labs actually change management? Our experts debate fasting insulin versus A1c, explain why total testosterone can mislead, and share the LH-to-FSH trick that helps settle ambiguous cases.
Most patients meet PMOS in a primary care office first. Our experts map the referral threshold and argue insulin resistance — not just androgens — should drive how aggressively PCPs treat.
Ovarian ultrasound doesn't apply to teens. Our experts walk through the 2-criteria threshold for adolescents, the "at risk" category, and why untreated menstrual irregularity carries real long-term consequences.
A global Lancet consensus just renamed PCOS to PMOS. Our experts explain why the shift moves care beyond the ovaries — and what it means for how clinicians talk to patients today.
FDA authorized Abbott's Libre Duo 10 Day, the first wearable that continuously tracks glucose and ketones, for patients 2 and older with diabetes.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FDA approves baricitinib for adolescents with severe alopecia areata
2
FDA approves obinutuzumab to reduce relapse risk in childhood-onset idiopathic nephrotic syndrome
3
GLP-1 receptor agonists tied to nutritional deficiencies in children, study finds
4
FAQ: How should pediatricians hand off teens with diabetes?
5